{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:22:26Z","timestamp":1789129346992,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40272-024-00634-w","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T14:02:18Z","timestamp":1716472938000},"page":"459-467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Inotuzumab Ozogamicin: First Pediatric Approval"],"prefix":"10.1007","volume":"26","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"1","key":"634_CR1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3892\/ol.2020.11583","volume":"20","author":"FL Huang","year":"2020","unstructured":"Huang FL, Liao EC, Li CL, et al. Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: molecular pathways and disease treatments. Oncol Lett. 2020;20(1):448\u201354.","journal-title":"Oncol Lett"},{"issue":"5","key":"634_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40272-020-00413-3","volume":"22","author":"S Jasinski","year":"2020","unstructured":"Jasinski S, De Los Reyes FA, Yametti GC, et al. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia: advances and ongoing challenges. Paediatr Drugs. 2020;22(5):485\u201399.","journal-title":"Paediatr Drugs"},{"issue":"5","key":"634_CR3","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","volume":"103","author":"JF DiJoseph","year":"2004","unstructured":"DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103(5):1807\u201314.","journal-title":"Blood"},{"issue":"1","key":"634_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40164-023-00454-7","volume":"12","author":"J Xu","year":"2023","unstructured":"Xu J, Luo W, Li C, et al. Targeting CD22 for B-cell hematologic malignancies. Exp Hematol Oncol. 2023;12(1):90.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"634_CR5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/pbc.25410","volume":"62","author":"NN Shah","year":"2015","unstructured":"Shah NN, Stevenson MS, Yuan CM, et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62(6):964\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"634_CR6","unstructured":"US Food & Drug Administration. FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia [media release]. 6 Mar 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-inotuzumab-ozogamicin-pediatric-patients-acute-lymphoblastic-leukemia."},{"key":"634_CR7","unstructured":"Pfizer Limited. BESPONSA (inotuzumab ozogamicin): US prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761040s003lbl.pdf. Accessed 2 Apr 2024."},{"key":"634_CR8","unstructured":"Pfizer. Besponsa\u00ae for intravenous infusion receives approval for dosage and administration for children with relapsed or refractory CD22-positive acute lymphoblastic leukemia [media release]. 26 Mar 2024. https:\/\/www.pfizer.co.jp\/pfizer\/company\/press\/2024\/2024-03-26-05."},{"key":"634_CR9","unstructured":"Celltech Group PLC. Annual report, 2003. 2003. https:\/\/www.sec.gov\/Archives\/edgar\/data\/877799\/000119312504108577\/d20f.htm. Accessed 27 Mar 2024."},{"key":"634_CR10","unstructured":"Pfizer. Pfizer Receives U.S. FDA Approval for BESPONSA\u00ae (inotuzumab ozogamicin) [media release]. 17 Aug 2017. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_receives_u_s_fda_approval_for_besponsa_inotuzumab_ozogamicin."},{"issue":"2","key":"634_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/leu.2011.206","volume":"26","author":"JF de Vries","year":"2012","unstructured":"de Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26(2):255\u201364.","journal-title":"Leukemia"},{"issue":"11","key":"634_CR12","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","volume":"21","author":"JF DiJoseph","year":"2007","unstructured":"DiJoseph JF, Dougher MM, Armellino DC, et al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21(11):2240\u20135.","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"634_CR13","doi-asserted-by":"publisher","first-page":"8845","DOI":"10.1182\/blood-2022-165954","volume":"140","author":"E Pennesi","year":"2022","unstructured":"Pennesi E, Brivio E, Pelletier KB, et al. Population pharmacokinetics of inotuzumab ozogamicin (InO) as single agent in pediatric relapsed\/refractory acute lymphoblastic leukemia: results from the ITCC-059 phase IA and phase II trial [abstract no. 3987]. Blood. 2022;140(Suppl 1):8845\u20137.","journal-title":"Blood"},{"issue":"12","key":"634_CR14","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1182\/blood.2020007848","volume":"137","author":"E Brivio","year":"2021","unstructured":"Brivio E, Locatelli F, Lopez-Yurda M, et al. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood. 2021;137(12):1582\u201390.","journal-title":"Blood"},{"issue":"6","key":"634_CR15","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","volume":"36","author":"E Pennesi","year":"2022","unstructured":"Pennesi E, Michels N, Brivio E, et al. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia. 2022;36(6):1516\u201324.","journal-title":"Leukemia"},{"key":"634_CR16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284409","author":"E Pennesi","year":"2024","unstructured":"Pennesi E, Brivio E, Ammerlaan ACJ, et al. Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial. Haematologica. 2024. https:\/\/doi.org\/10.3324\/haematol.2023.284409.","journal-title":"Haematologica"},{"issue":"9","key":"634_CR17","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.21.01693","volume":"40","author":"MM O'Brien","year":"2022","unstructured":"O\u2019Brien MM, Ji L, Shah NN, et al. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Protocol AALL1621. J Clin Oncol. 2022;40(9):956\u201367.","journal-title":"J Clin Oncol"},{"issue":"1","key":"634_CR18","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1111\/bjh.16732","volume":"190","author":"C Calvo","year":"2020","unstructured":"Calvo C, Cabannes-Hamy A, Adjaoud D, et al. Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia. Br J Haematol. 2020;190(1):e53\u20136.","journal-title":"Br J Haematol"},{"issue":"4","key":"634_CR19","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","volume":"33","author":"D Bhojwani","year":"2019","unstructured":"Bhojwani D, Sposto R, Shah NN, et al. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia. 2019;33(4):884\u201392.","journal-title":"Leukemia"},{"issue":"1","key":"634_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.24287\/1726-1708-2023-22-1-46-52","volume":"22","author":"DA Evstratov","year":"2023","unstructured":"Evstratov DA, Shutova AD, Dyakonova YY, et al. The use of inotuzumab ozogamicin in children with relapsed\/refractory B-lineage acute lymphoblastic leukemia. Pediatr Hematol Oncol Immunopathol. 2023;22(1):46\u201352.","journal-title":"Pediatr Hematol Oncol Immunopathol"},{"issue":"2","key":"634_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/pbc.24721","volume":"61","author":"M Rytting","year":"2014","unstructured":"Rytting M, Triche L, Thomas D, et al. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61(2):369\u201372.","journal-title":"Pediatr Blood Cancer"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00634-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-024-00634-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00634-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T06:33:37Z","timestamp":1718951617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-024-00634-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["634"],"URL":"https:\/\/doi.org\/10.1007\/s40272-024-00634-w","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"30 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}